CD274 and non-small cell lung carcinoma: While PD-L1 expression in the tumor cell (TPS) or combined positive scores (assessed as a combination of PD-L1 on tumor and immune cells) are being used as predictive biomarkers in other malignancies such as esophageal, urothelial, and non-small cell lung cancer, PD-L1 CPS ≥ 1% did not correlate with the OS in pembrolizumab (KEYNOTE-224) and nivolumab (CHECKMATE-459) trials [16,41].